AAN 2026 18 - 22 April 2026

Effects of Semaglutide on Alzheimer’s Disease-Related Biological Processes: Results from a Biofluid Biomarker and Multiomics Immunophenotyping Phase 3 Study in Patients with Early Alzheimer’s Disease After 12 Weeks of Treatment

Authors :

Kristian Frederiksen¹; Paul Mystkowski²; Marie Bentsen³; Dylan Belmont-Rausch³; Lisbeth Carstensen³; Brian Cutler⁴; Redwan Farooq⁴; Lea Hildebrandt³; Martí Jiménez-Mausbach³; Peter Johannsen³; Gabriel Martino³; Joseph Polex-Wolf³; Amaya Zaratiegui³; Giovanni B. Frisoni⁵; Kate Attfield⁴; Lotte Knudsen³;

Affiliations

View Details Hide Details

Keywords

Neurology

Congress oral presentation

GLP-1 RA

Semaglutide

PHASE 3 (RCT)

Search Science Hub

Are you a healthcare professional?

Effects of Semaglutide on Alzheimer’s Disease-Related Biological Processes: Results from a Biofluid Biomarker and Multiomics Immunophenotyping Phase 3 Study in Patients with Early Alzheimer’s Disease After 12 Weeks of Treatment